Evolus, Inc.
Evolus, Inc. is a U.S.-based performance beauty company focused on cash-pay medical aesthetics. It commercializes Jeuveau®, a botulinum toxin for glabellar lines, and has begun launching Evolysse™, a line of injectable hyaluronic acid gels for wrinkles and folds.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueJeuveau® is the company's commercial botulinum toxin product used by aesthetic practitioners for glabellar lines.
Evolysse™ is a collection of HA fillers for wrinkles, folds, and facial contour applications.
Loyalty, pricing, and co-branded marketing programs that support practitioner adoption and repeat purchasing.
Products
Reported · share of revenue- Products99.3 %
- Services0.7 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Evolus sells primarily to licensed aesthetic practitioners who administer injectable treatments in the cash-pay beauty market. Demand is driven by clinics and providers seeking differentiated products, marketing support, and flexible pricing rather than reimbursement-based therapeutic products. The company also indirectly serves end consumers who pay out of pocket for aesthetic procedures.
Buy Jeuveau® and Evolysse™ to perform elective injectable treatments and retain patients in cash-pay aesthetics.
Purchase products for recurring facial aesthetic procedures and respond to pricing, loyalty, and bundled offers.
Use the products as part of broader aesthetic service menus and value clinical data and product differentiation.
Help commercialize Jeuveau® and future Evolysse™ launches outside the U.S. where direct sales are not used.
Strategy
Evolus is building a cash-pay aesthetics franchise around Jeuveau® and the Evolysse™ filler line, using an aesthetic-only model to avoid reimbursement complexity and preserve pricing flexibility. Its strategy combines U.S. expansion, international launches, and digital customer engagement to grow practitioner adoption and broaden the product portfolio.
Jeuveau® is the core commercial product and funds the platform.
The HA filler line expands the addressable market and diversifies revenue.
A broader portfolio improves customer retention and competitive positioning.
Geography
2024Evolus is headquartered in the United States and generates most revenue there, with Jeuveau® also sold in Canada, certain European countries, and Australia. The company launched Evolysse™ Form and Smooth in the U.S. in April 2025 and expects broader European launches in 2026, making international approvals and market access important to growth.
Share of the revenue the company reports by geography.
Risks
Evolus depends on continued adoption of elective aesthetic procedures, so consumer spending weakness, inflation, and tariffs can pressure demand and margins. The company also faces execution risk around regulatory approvals, international launches, and reliance on third-party manufacturers and partners for supply and commercialization.
- Dependence on elective consumer spendingImpact: HighLikelihood: High
Customers pay out of pocket, so demand is sensitive to confidence, inflation, and economic stress.
Exposure: Jeuveau® and Evolysse™ procedure volumes
- Tariffs and supply-chain cost inflationImpact: HighLikelihood: High
The company imports products and components through third-party manufacturers, making costs vulnerable to trade actions.
Exposure: Gross margin and inventory planning
- Regulatory approval and launch timingImpact: HighLikelihood: Medium
Future Evolysse™ products require FDA and other approvals before commercialization.
Exposure: Revenue timing and product pipeline
- Manufacturing concentrationImpact: MediumLikelihood: Medium
Jeuveau® and Evolysse™ rely on Daewoong and Symatese for production and supply.
Exposure: Product availability and quality control
- Competitive pricing pressureImpact: MediumLikelihood: Medium
Large aesthetics competitors can use rebates, coupons, and bundling to defend share.
Exposure: Market share and average selling price
Accounting
Judgemental itemsGross sales are reduced by rebates, loyalty rewards, and marketing programs, affecting reported revenue and comparability.
Impact: Net revenue and gross margin
Canadian Jeuveau® sales through a partner are recorded on a net basis as service revenue rather than product revenue.
Impact: Revenue mix and margin presentation
The liability is valued using projected revenues, discount rates, and timing assumptions, creating earnings volatility.
Impact: Operating expenses and balance sheet liabilities
Inventory purchases for Evolysse™ launches and tariff protection can affect cash flow and period-end inventory balances.
Impact: Working capital and cash flow
Similar listed companies
Publicly listed companies with a comparable business focus.
Evolent Health, Inc.
EVH · Services-Management Services
Evolution
EVO · Consumer Discretionary
Evolution is a prominent provider of online casino games, specializing in both Live Casino and Random Number Generator (RNG) games.
AbbVie Inc.
ABBV · Pharmaceutical Preparations
Evolv Technologies Holdings, Inc.
EVLV · Computer Peripheral Equipment, NEC
Evofem Biosciences, Inc.
EVFM · Pharmaceutical Preparations
Evommune, Inc.
EVMN · Pharmaceutical Preparations
Last updated: 24/09/2026